Haiyan Xu1,2, Chen Ma1,2, Feiyan Zhao1,2, Ping Chen3, Yahua Liu1,2, Zhihong Sun1,2, Lihong Cui4, Lai-Yu Kwok5,6, Heping Zhang7,8. 1. Key Laboratory of Dairy Biotechnology and Engineering, Ministry of Education P.R.C., Inner Mongolia Agricultural University, Huhhot, 010018, People's Republic of China. 2. Key Laboratory of Dairy Products Processing, Ministry of Agriculture and Rural Affairs P.R.C., Inner Mongolia Agricultural University, Huhhot, 010018, People's Republic of China. 3. Affiliated Hospital of Inner Mongolia Medical University, Hohhot, 010050, People's Republic of China. 4. Department of Gastroenterology, Navy General Hospital of PLA, Beijing, 100048, People's Republic of China. 5. Key Laboratory of Dairy Biotechnology and Engineering, Ministry of Education P.R.C., Inner Mongolia Agricultural University, Huhhot, 010018, People's Republic of China. kwok_ly@yahoo.com. 6. Key Laboratory of Dairy Products Processing, Ministry of Agriculture and Rural Affairs P.R.C., Inner Mongolia Agricultural University, Huhhot, 010018, People's Republic of China. kwok_ly@yahoo.com. 7. Key Laboratory of Dairy Biotechnology and Engineering, Ministry of Education P.R.C., Inner Mongolia Agricultural University, Huhhot, 010018, People's Republic of China. hepingdd@vip.sina.com. 8. Key Laboratory of Dairy Products Processing, Ministry of Agriculture and Rural Affairs P.R.C., Inner Mongolia Agricultural University, Huhhot, 010018, People's Republic of China. hepingdd@vip.sina.com.
Abstract
PURPOSE:Irritable bowel syndrome (IBS) is a functional bowel disorder. This study aimed to assess the effect of a probiotic product (containing Lactobacillus casei Zhang, Lactobacillus plantarum P-8, and Bifdobacterium animalis subsp. lactis V9) as an adjunct to a routine regimen in IBS management. METHODS:Forty-five patients with IBS were randomized into the probiotic (n = 24) and control (n = 21) groups, receiving the routine regimen with or without probiotics for 28 days, respectively. Serum and fecal samples were collected and analyzed. RESULTS: The IBS-symptom severity score (P < 0.01), serum levels of IL-6 (P < 0.01) and TNF-α (P < 0.001) were significantly lower in the probiotic group than the control group at day 28. The probiotic adjunctive treatment resulted in significant decreases in some bacterial genera that worsen IBS, such as Bacteroides (P < 0.01), Escherichia (P < 0.05), and Citrobacter (P < 0.05), significant decreases were also observed in some beneficial genera in the control group, including Bifidobacterium (P < 0.05), Eubacterium (P < 0.05), Dorea (P < 0.01), and Butyricicoccus (P < 0.05). Furthermore, significant correlations were found between some monitored parameters and compositional changes in the fecal microbiota, suggesting that the clinical improvement of IBS was likely associated with gut microbiota modulation. The enterotype analysis revealed that the initial fecal microbiota composition could influence clinical outcomes. CONCLUSIONS: The adjunctive use of probiotics with a routine regimen showed additional clinical effectiveness compared to the routine regimen alone in managing IBS. A pretreatment gut microbiome analysis might help tailor a personalized probiotic regimen to optimize treatment effects.
RCT Entities:
PURPOSE:Irritable bowel syndrome (IBS) is a functional bowel disorder. This study aimed to assess the effect of a probiotic product (containing Lactobacillus casei Zhang, Lactobacillus plantarum P-8, and Bifdobacterium animalis subsp. lactis V9) as an adjunct to a routine regimen in IBS management. METHODS: Forty-five patients with IBS were randomized into the probiotic (n = 24) and control (n = 21) groups, receiving the routine regimen with or without probiotics for 28 days, respectively. Serum and fecal samples were collected and analyzed. RESULTS: The IBS-symptom severity score (P < 0.01), serum levels of IL-6 (P < 0.01) and TNF-α (P < 0.001) were significantly lower in the probiotic group than the control group at day 28. The probiotic adjunctive treatment resulted in significant decreases in some bacterial genera that worsen IBS, such as Bacteroides (P < 0.01), Escherichia (P < 0.05), and Citrobacter (P < 0.05), significant decreases were also observed in some beneficial genera in the control group, including Bifidobacterium (P < 0.05), Eubacterium (P < 0.05), Dorea (P < 0.01), and Butyricicoccus (P < 0.05). Furthermore, significant correlations were found between some monitored parameters and compositional changes in the fecal microbiota, suggesting that the clinical improvement of IBS was likely associated with gut microbiota modulation. The enterotype analysis revealed that the initial fecal microbiota composition could influence clinical outcomes. CONCLUSIONS: The adjunctive use of probiotics with a routine regimen showed additional clinical effectiveness compared to the routine regimen alone in managing IBS. A pretreatment gut microbiome analysis might help tailor a personalized probiotic regimen to optimize treatment effects.
Authors: Jennifer S Labus; Emily B Hollister; Jonathan Jacobs; Kyleigh Kirbach; Numan Oezguen; Arpana Gupta; Jonathan Acosta; Ruth Ann Luna; Kjersti Aagaard; James Versalovic; Tor Savidge; Elaine Hsiao; Kirsten Tillisch; Emeran A Mayer Journal: Microbiome Date: 2017-05-01 Impact factor: 14.650